BioWorld

May 17, 2010

View Archived Issues

Pharma Outlicensing: From Opportunism to R&D Funding

A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying. Read More

Money Raised Year to Date

Read More

Savient for Sale, Ardea Bid Adds Dose: Gout on Move

Read More

German Plan: Blood in Water for Overseas Reimbursement?

Read More

Money Raised By Biotech in 2010

Read More

Week in Review

Read More

Word on the Street

Read More

FDA Approvals in April

Read More

Phase I Clinical Trials Update: April 2010

Read More

Phase II Clinical Trials Update: April 2010

Read More

Pivotal/Phase III Clinical Trials Update: April 2010

Read More

Non-U.S. Clinical Trials And Regulatory Actions: April 2010

Read More

FDA Submissions, Approvals And Other Actions: April 2010

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More